AAPL344.08+0.62 (+0.18%) ▲|ABBV286.06+0.59 (+0.20%) ▲|ABT104.29-0.60 (-0.57%) ▼|ACN230.61+0.93 (+0.40%) ▲|ADBE244.41-0.79 (-0.32%) ▼|AMAT421.96+12.67 (+3.10%) ▲|AMD540.64+11.89 (+2.25%) ▲|AMGN434.25+1.76 (+0.41%) ▲|AMT183.31-1.97 (-1.06%) ▼|AMZN258.92+8.92 (+3.57%) ▲|AVGO334.25+5.50 (+1.67%) ▲|AXP312.21-1.39 (-0.44%) ▼|BA189.44-0.77 (-0.41%) ▼|BAC51.26+0.03 (+0.05%) ▲|BKNG161.16-2.29 (-1.40%) ▼|BLK1,126.78-7.61 (-0.67%) ▼|BMY59.45-0.31 (-0.51%) ▼|BNY142.95-0.35 (-0.24%) ▼|BRK-B532.17+0.15 (+0.03%) ▲|C123.90-0.36 (-0.29%) ▼|CAT722.74-8.02 (-1.10%) ▼|CL93.46-0.66 (-0.70%) ▼|CMCSA21.58-0.33 (-1.48%) ▼|COF200.20-1.54 (-0.76%) ▼|COP145.61-0.90 (-0.61%) ▼|COST989.96+0.85 (+0.09%) ▲|CRM239.21-1.49 (-0.62%) ▼|CSCO107.25-0.15 (-0.14%) ▼|CVS92.02-0.34 (-0.37%) ▼|CVX224.78-0.21 (-0.09%) ▼|DE632.60-9.26 (-1.44%) ▼|DHR227.27-1.77 (-0.77%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK120.08-1.39 (-1.14%) ▼|EMR161.30-0.17 (-0.11%) ▼|FDX293.24-0.31 (-0.11%) ▼|GD341.97-2.18 (-0.63%) ▼|GE312.56-1.27 (-0.40%) ▼|GEV921.53+0.33 (+0.04%) ▲|GILD157.11+0.92 (+0.59%) ▲|GM83.24-0.72 (-0.86%) ▼|GOOG340.45+3.54 (+1.05%) ▲|GOOGL344.08+3.49 (+1.02%) ▲|GS883.89+2.63 (+0.30%) ▲|HD307.76-1.87 (-0.60%) ▼|HON210.27-1.14 (-0.54%) ▼|IBM233.66+1.52 (+0.65%) ▲|INTC93.76+3.91 (+4.35%) ▲|INTU319.82-5.33 (-1.64%) ▼|ISRG430.82+4.12 (+0.96%) ▲|JNJ254.13-1.44 (-0.56%) ▼|JPM338.06-1.66 (-0.49%) ▼|KO93.79-0.11 (-0.12%) ▼|LIN502.01+3.58 (+0.72%) ▲|LLY1,258.36+1.33 (+0.11%) ▲|LMT545.83-6.26 (-1.13%) ▼|LOW195.77-1.61 (-0.82%) ▼|LRCX275.08+11.14 (+4.22%) ▲|MA615.91-1.51 (-0.24%) ▼|MCD241.32-1.66 (-0.68%) ▼|MDLZ63.88-0.03 (-0.05%) ▼|MDT94.07-0.68 (-0.72%) ▼|META694.58-14.75 (-2.08%) ▼|MMM162.89-1.86 (-1.13%) ▼|MO74.42-0.69 (-0.92%) ▼|MRK146.87+0.92 (+0.63%) ▲|MS180.72+0.15 (+0.08%) ▲|MSFT533.03+3.98 (+0.75%) ▲|MU908.23+29.39 (+3.34%) ▲|NEE78.59-1.21 (-1.52%) ▼|NFLX69.30-1.24 (-1.75%) ▼|NKE36.83-0.31 (-0.82%) ▼|NOW143.33+1.36 (+0.96%) ▲|NVDA215.88+1.75 (+0.82%) ▲|ORCL129.36+1.13 (+0.88%) ▲|PEP132.26+0.77 (+0.59%) ▲|PFE29.61+0.03 (+0.08%) ▲|PG158.10-1.25 (-0.78%) ▼|PLTR191.30+5.27 (+2.83%) ▲|PM202.50-2.70 (-1.32%) ▼|QCOM175.67+3.56 (+2.07%) ▲|RTX191.84-2.08 (-1.07%) ▼|SBUX97.14-0.38 (-0.39%) ▼|SCHW90.36-1.60 (-1.74%) ▼|SO89.93-1.25 (-1.37%) ▼|SPG204.06-1.38 (-0.67%) ▼|T23.27-0.18 (-0.75%) ▼|TMO688.56-1.44 (-0.21%) ▼|TMUS157.97-1.13 (-0.71%) ▼|TSLA361.84+7.12 (+2.01%) ▲|TXN276.46-0.03 (-0.01%) ▼|UBER70.27-0.09 (-0.12%) ▼|UNH404.58+3.15 (+0.78%) ▲|UNP287.20-1.84 (-0.64%) ▼|UPS97.27-0.21 (-0.22%) ▼|USB58.37-0.37 (-0.62%) ▼|V402.56-0.05 (-0.01%) ▼|VZ44.39-0.40 (-0.89%) ▼|WFC83.12-0.75 (-0.89%) ▼|WMT118.71-0.10 (-0.08%) ▼|XOM178.01-0.98 (-0.54%) ▼|AAPL344.08+0.62 (+0.18%) ▲|ABBV286.06+0.59 (+0.20%) ▲|ABT104.29-0.60 (-0.57%) ▼|ACN230.61+0.93 (+0.40%) ▲|ADBE244.41-0.79 (-0.32%) ▼|AMAT421.96+12.67 (+3.10%) ▲|AMD540.64+11.89 (+2.25%) ▲|AMGN434.25+1.76 (+0.41%) ▲|AMT183.31-1.97 (-1.06%) ▼|AMZN258.92+8.92 (+3.57%) ▲|AVGO334.25+5.50 (+1.67%) ▲|AXP312.21-1.39 (-0.44%) ▼|BA189.44-0.77 (-0.41%) ▼|BAC51.26+0.03 (+0.05%) ▲|BKNG161.16-2.29 (-1.40%) ▼|BLK1,126.78-7.61 (-0.67%) ▼|BMY59.45-0.31 (-0.51%) ▼|BNY142.95-0.35 (-0.24%) ▼|BRK-B532.17+0.15 (+0.03%) ▲|C123.90-0.36 (-0.29%) ▼|CAT722.74-8.02 (-1.10%) ▼|CL93.46-0.66 (-0.70%) ▼|CMCSA21.58-0.33 (-1.48%) ▼|COF200.20-1.54 (-0.76%) ▼|COP145.61-0.90 (-0.61%) ▼|COST989.96+0.85 (+0.09%) ▲|CRM239.21-1.49 (-0.62%) ▼|CSCO107.25-0.15 (-0.14%) ▼|CVS92.02-0.34 (-0.37%) ▼|CVX224.78-0.21 (-0.09%) ▼|DE632.60-9.26 (-1.44%) ▼|DHR227.27-1.77 (-0.77%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK120.08-1.39 (-1.14%) ▼|EMR161.30-0.17 (-0.11%) ▼|FDX293.24-0.31 (-0.11%) ▼|GD341.97-2.18 (-0.63%) ▼|GE312.56-1.27 (-0.40%) ▼|GEV921.53+0.33 (+0.04%) ▲|GILD157.11+0.92 (+0.59%) ▲|GM83.24-0.72 (-0.86%) ▼|GOOG340.45+3.54 (+1.05%) ▲|GOOGL344.08+3.49 (+1.02%) ▲|GS883.89+2.63 (+0.30%) ▲|HD307.76-1.87 (-0.60%) ▼|HON210.27-1.14 (-0.54%) ▼|IBM233.66+1.52 (+0.65%) ▲|INTC93.76+3.91 (+4.35%) ▲|INTU319.82-5.33 (-1.64%) ▼|ISRG430.82+4.12 (+0.96%) ▲|JNJ254.13-1.44 (-0.56%) ▼|JPM338.06-1.66 (-0.49%) ▼|KO93.79-0.11 (-0.12%) ▼|LIN502.01+3.58 (+0.72%) ▲|LLY1,258.36+1.33 (+0.11%) ▲|LMT545.83-6.26 (-1.13%) ▼|LOW195.77-1.61 (-0.82%) ▼|LRCX275.08+11.14 (+4.22%) ▲|MA615.91-1.51 (-0.24%) ▼|MCD241.32-1.66 (-0.68%) ▼|MDLZ63.88-0.03 (-0.05%) ▼|MDT94.07-0.68 (-0.72%) ▼|META694.58-14.75 (-2.08%) ▼|MMM162.89-1.86 (-1.13%) ▼|MO74.42-0.69 (-0.92%) ▼|MRK146.87+0.92 (+0.63%) ▲|MS180.72+0.15 (+0.08%) ▲|MSFT533.03+3.98 (+0.75%) ▲|MU908.23+29.39 (+3.34%) ▲|NEE78.59-1.21 (-1.52%) ▼|NFLX69.30-1.24 (-1.75%) ▼|NKE36.83-0.31 (-0.82%) ▼|NOW143.33+1.36 (+0.96%) ▲|NVDA215.88+1.75 (+0.82%) ▲|ORCL129.36+1.13 (+0.88%) ▲|PEP132.26+0.77 (+0.59%) ▲|PFE29.61+0.03 (+0.08%) ▲|PG158.10-1.25 (-0.78%) ▼|PLTR191.30+5.27 (+2.83%) ▲|PM202.50-2.70 (-1.32%) ▼|QCOM175.67+3.56 (+2.07%) ▲|RTX191.84-2.08 (-1.07%) ▼|SBUX97.14-0.38 (-0.39%) ▼|SCHW90.36-1.60 (-1.74%) ▼|SO89.93-1.25 (-1.37%) ▼|SPG204.06-1.38 (-0.67%) ▼|T23.27-0.18 (-0.75%) ▼|TMO688.56-1.44 (-0.21%) ▼|TMUS157.97-1.13 (-0.71%) ▼|TSLA361.84+7.12 (+2.01%) ▲|TXN276.46-0.03 (-0.01%) ▼|UBER70.27-0.09 (-0.12%) ▼|UNH404.58+3.15 (+0.78%) ▲|UNP287.20-1.84 (-0.64%) ▼|UPS97.27-0.21 (-0.22%) ▼|USB58.37-0.37 (-0.62%) ▼|V402.56-0.05 (-0.01%) ▼|VZ44.39-0.40 (-0.89%) ▼|WFC83.12-0.75 (-0.89%) ▼|WMT118.71-0.10 (-0.08%) ▼|XOM178.01-0.98 (-0.54%) ▼|
10.9 C
New York
Monday, October 19, 2026

Tag: headache

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHeadache